About Evoxx Technologies
Evoxx Technologies is a company based in Monheim Am Rhein (Germany) founded in 2006 was acquired by Advanced Enzyme Technologies in July 2017. The company has 15 employees as of December 31, 2022. Evoxx Technologies offers products and services including Food Processing Enzymes, Biocatalysis Enzymes, and Human Nutrition Enzymes. Evoxx Technologies operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Monheim Am Rhein, Germany
- Employees 15 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Evoxx Technologies Gmbh
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$553.8 K (USD), Grant
Apr 01, 2015
-
Investors
Advanced Enzyme Technologies
& 2 more
-
Employee Count
15
as on Dec 31, 2022
-
Acquired by
Advanced Enzyme Technologies
(Jul 27, 2017)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Evoxx Technologies
Evoxx Technologies offers a comprehensive portfolio of products and services, including Food Processing Enzymes, Biocatalysis Enzymes, and Human Nutrition Enzymes.
Enzymes used for processing food products efficiently
Enzymes for chemical and pharma production processes
Enzymes as active ingredients in pharmaceutical formulations
Funding Insights of Evoxx Technologies
Investors in Evoxx Technologies
Evoxx Technologies has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Advanced Enzyme Technologies, European Union and High-Tech Gründerfonds.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage investments are made in high-tech startups by HTGF.
|
Locked | Locked | Locked | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked | |
|
Enzymes are manufactured for nutrition, food, feed, and textile industries.
|
Locked | Locked | Locked |
Investor details for Evoxx Technologies
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Evoxx Technologies
Investment portfolio details for Evoxx Technologies
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Evoxx Technologies
Detailed financials for Evoxx Technologies
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Evoxx Technologies Comparisons
Peer comparison for Evoxx Technologies
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Evoxx Technologies
Evoxx Technologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
Detailed competitors of Evoxx Technologies
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Evoxx Technologies
Complete news archive for Evoxx Technologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Evoxx Technologies
Evoxx Technologies was founded in 2006 and raised its 1st funding round 1 year after it was founded.
Evoxx Technologies is headquartered in Monheim Am Rhein, Germany. It is registered at Monheim Am Rhein, Nordrhein-westfalen, Germany.
As of Dec 31, 2022, the latest employee count at Evoxx Technologies is 15.
Evoxx Technologies was established in 2006 as a spin-off from the Institute of Molecular Enzyme Technology at Heinrich-Heine University in Dusseldorf and Forschungszentrum Julich. Enzymes and biocatalytic processes are developed for the chemical and pharmaceutical sectors. A range of enzymes and customized bio-catalysts is provided for applications including textiles, adhesives, nutrition, and refinement processes. Laboratories adhere to S1 and S2 standards, with development scaled to commercial levels in Germany.
Evoxx Technologies's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Evoxx Technologies offers Food Processing Enzymes, Biocatalysis Enzymes, and Human Nutrition Enzymes.
Evoxx Technologies has 3 investors. Key investors include Advanced Enzyme Technologies, European Union, and High-Tech Gründerfonds.